Bayer 20414: A multicenter, non-randomized, open-label, multiple dose escalation study to evaluate the safety and tolerability of subcutaneous BAY 1093884 in males with hemophilia
|Effective start/end date||3/11/19 → 3/30/24|
- BAYER HEALTHCARE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.